Loading...
Market
When will Bavarian Nordic's mpox vaccine be approved for adolescents by the EU by Q1 2025?
2
Resolution / Starting Odds
Approved by Q3 2024 • 25%
Approved by Q4 2024 • 25%
Approved by Q1 2025 • 25%
Not approved by Q1 2025 • 25%
European Medicines Agency (EMA) official announcements
Story
Bavarian Nordic Seeks Critical EU Approval for Mpox Vaccine in Adolescents Aged 12 to 17
Aug 16, 2024, 11:04 AM
Danish biotech company Bavarian Nordic has submitted data to the European Union's drug regulator seeking approval to extend the use of its mpox vaccine to adolescents aged 12 to 17. This move follows the World Health Organization's declaration of a global public health emergency due to a surge in mpox cases. CEO Paul Chaplin emphasized the importance of this approval, describing it as 'critical' for addressing the health crisis.
View original story
Similar markets
Yes • 50%
No • 50%
Approved without conditions • 25%
Approved with conditions • 25%
Not approved • 25%
Decision delayed • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Less than 30% • 25%
30% to 50% • 25%
50% to 70% • 25%
More than 70% • 25%
Less than 1 million • 25%
1 to 3 million • 25%
3 to 5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
